The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Open accessAbstract
BACKGROUND: Cryptococcal meningitis accounts for more than 100,000 human immunodeficiency virus (HIV)-related deaths per year. We tested two treatment strategies that could be more sustainable in Africa than the standard of 2 weeks of amphotericin B plus flucytosine and more effective than the widely used fluconazole monotherapy. METHODS: We randomly assigned HIV-infected adults with cryptococcal meningitis to receive an oral regimen (fluconazole [1200 mg per day] plus flucytosine [100 mg per kilogram of body weight per day] for 2 weeks), 1 week of amphotericin B (1 mg per kilogram per day), or 2 weeks of amphotericin B (1 mg per kilogram per day). Each patient assigned to receive amphotericin B was also randomly assigned to receive fluconazole or flucytosine as a partner drug. After induction treatment, all the patients received fluconazole consolidation therapy and were followed to 10 weeks. RESULTS: A total of 721 patients underwent randomization. Mortality in the oral-regimen, 1-week amphotericin B, and 2-week amphotericin B groups was 18.2% (41 of 225), 21.9% (49 of 224), and 21.4% (49 of 229), respectively, at 2 weeks and was 35.1% (79 of 225), 36.2% (81 of 224), and 39.7% (91 of 229), respectively, at 10 weeks. The upper limit of the one-sided 97.5% confidence interval for the difference in 2-week mortality was 4.2 percentage points for the oral-regimen group versus the 2-week amphotericin B groups and 8.1 percentage points for the 1-week amphotericin B groups versus the 2-week amphotericin B groups, both of which were below the predefined 10-percentage-point noninferiority margin. As a partner drug with amphotericin B, flucytosine was superior to fluconazole (71 deaths [31.1%] vs. 101 deaths [45.0%]; hazard ratio for death at 10 weeks, 0.62; 95% confidence interval [CI], 0.45 to 0.84; P=0.002). One week of amphotericin B plus flucytosine was associated with the lowest 10-week mortality (24.2%; 95% CI, 16.2 to 32.1). Side effects, such as severe anemia, were more frequent with 2 weeks than with 1 week of amphotericin B or with the oral regimen. CONCLUSIONS: One week of amphotericin B plus flucytosine and 2 weeks of fluconazole plus flucytosine were effective as induction therapy for cryptococcal meningitis in resource-limited settings. (ACTA Current Controlled Trials number, ISRCTN45035509 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationPark, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861
Self-citationCombination Antifungal Therapy for Cryptococcal Meningitis
Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 545
Self-citationCombination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
Brouwer, A. E., Rajanuwong, A., Chierakul, W., Griffin, G. E., Larsen, R. A., White, N. J., & Harrison, T. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16301-0 · Cited by 470
Self-citationJarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367
Self-citationAdjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Beardsley, J., Wolbers, M., Kibengo, F. M., Ggayi, A.-B. M., Kamali, A., Cuc, N. T. K., Binh, T. Q., Chau, N. V. V., Farrar, J., Merson, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509024 · Cited by 315
Self-citationAdult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases
Jarvis, J. N., Meintjes, G., Williams, A., Brown, Y., Crede, T., & Harrison, T. S. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-67 · Cited by 266
Self-citationBicanic, T., Muzoora, C., Brouwer, A. E., Meintjes, G., Longley, N., Taseera, K., Rebe, K., Loyse, A., Jarvis, J., Bekker, L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604716 · Cited by 227
Self-citationLongley, N., Muzoora, C., Taseera, K., Mwesigye, J., Rwebembera, J., Chakera, A., Wall, E., Andia, I., Jaffar, S., & Harrison, T. S. (2008) · Clinical Infectious Diseases · doi:10.1086/593194 · Cited by 202
Self-citation
Cited by
Tackling the emerging threat of antifungal resistance to human health
Fisher, M. C., Alastruey-Izquierdo, A., Berman, J., Bicanic, T., Bignell, E. M., Bowyer, P., Bromley, M., Brüggemann, R., Garber, G., Cornely, O. A., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00720-1 · Cited by 1,179
Self-citationTreatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363
Chang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Self-citationPulmonary cryptococcosis: A review of pathobiology and clinical aspects
Setianingrum, F., Rautemaa-Richardson, R., & Denning, D. W. (2019) · Medical Mycology · doi:10.1093/mmy/myy086 · Cited by 289
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Jarvis, J. N., Lawrence, D. S., Meya, D. B., Kagimu, E., Kasibante, J., Mpoza, E., Rutakingirwa, M. K., Ssebambulidde, K., Tugume, L., Rhein, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111904 · Cited by 286
Self-citationDynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., Segal, E. S., Needleman, L., Molloy, S. F., Kwon-Chung, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124516 · Cited by 167
“The ACTA trial, of which this is a substudy, recently reported the noninferiority of FLC plus 5FC combination therapy in terms of mortality outcomes compared with 2 weeks of AmB-based therapy, the long-standing gold standard, for induction treatment of HIV-related CM (40).”
MethodSelf-citationIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Billmyre, R. B., Applen Clancey, S., Li, L. X., Doering, T. L., & Heitman, J. (2020) · Nature Communications · doi:10.1038/s41467-019-13890-z · Cited by 102
Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi
Delma, F. Z., Al-Hatmi, A. M. S., Brüggemann, R. J. M., Melchers, W. J. G., de Hoog, S., Verweij, P. E., & Buil, J. B. (2021) · Journal of Fungi · doi:10.3390/jof7110909 · Cited by 96
“Furthermore, the association of 5-FC with fluconazole has shown a noninferiority with two weeks of amphotericin B-based therapy [13].”
BackgroundLoyse, A., Burry, J., Cohn, J., Ford, N., Chiller, T., Ribeiro, I., Koulla-Shiro, S., Mghamba, J., Ramadhani, A., Nyirenda, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30493-6 · Cited by 90
Self-citationJarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., Tlhako, N., Mawoko, N., Patel, R. K. K., Tenforde, M. W., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy515 · Cited by 86
Self-citationIn Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-21 · Cited by 78
“A combination of amphotericin B and flucytosine is a potent regimen and is known to be efficacious for other serious fungal infections, such as cryptococcal meningitis (21).”
BackgroundHope, W., Stone, N. R. H., Johnson, A., McEntee, L., Farrington, N., Santoro-Castelazo, A., Liu, X., Lucaci, A., Hughes, M., Oliver, J. D., et al. (2019) · mBio · doi:10.1128/mbio.02575-19 · Cited by 70
Self-citationNew antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Bastos, R. W., Freitas, G. J. C., Carneiro, H. C. S., Oliveira, L. V. N., Gouveia-Eufrasio, L., Santos, A. P. N., Moyrand, F., Maufrais, C., Janbon, G., & Santos, D. A. (2019) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.05.094 · Cited by 35
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., Chau, N. V. V., Binh, T. Q., Hung, L. Q., Beardsley, J., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15010.1 · Cited by 28
Self-citationGerlach, E. S., Altamirano, S., Yoder, J. M., Luggya, T. S., Akampurira, A., Meya, D. B., Boulware, D. R., Rhein, J., & Nielsen, K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.695240 · Cited by 17
Liu, J., Liu, J., Su, X., Yang, L., Wang, Y., Wang, A., Xu, X., Li, M., Jiang, Y., & Peng, F. (2022) · BMC Neurology · doi:10.1186/s12883-022-02803-1 · Cited by 14
Huang, Y., Zhang, Y., Yang, S., Lu, H., Yu, H., Wang, X., Jia, X., Tang, D., Wu, L., Huang, S., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00725-24 · Cited by 12
Metadata
- Authors
- Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., Chan, A. K., Stone, N., Kalata, N., Karunaharan, N., Gaskell, K., Peirse, M., Ellis, J., Chawinga, C., Lontsi, S., Ndong, J.-G., Bright, P., Lupiya, D., Chen, T., Bradley, J., Adams, J., van der Horst, C., van Oosterhout, J. J., Sini, V., Mapoure, Y. N., Mwaba, P., Bicanic, T., Lalloo, D. G., Wang, D., Hosseinipour, M. C., Lortholary, O., Jaffar, S., & Harrison, T. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-15
- Volume
- 378
- Issue
- 11
- Pages
- 1004-1017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2791888954
- Cited by
- 396
- References
- 26
- FWCI
- 29.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.